These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29569146)

  • 1. Anticoagulation in atrial fibrillation with heart failure.
    Zhao L; Wang WYS; Yang X
    Heart Fail Rev; 2018 Jul; 23(4):563-571. PubMed ID: 29569146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis.
    Mele M; Mele A; Imbrici P; Samarelli F; Purgatorio R; Dinoi G; Correale M; Nicolotti O; De Luca A; Brunetti ND; Liantonio A; Amoroso N
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of interactions between atrial fibrillation and heart failure.
    Khan MA; Satchithananda DK; Mamas MA
    Clin Med (Lond); 2016 Jun; 16(3):272-6. PubMed ID: 27251919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the Paradox: Can Anticoagulation Improve Outcomes in Patients With Heart Failure and Increased Bleeding Risk?
    Saeed D; Fuenmayor D; Niño Medina JA; Saleh I; Castiblanco Torres JD; Horn WL; Sosa Quintanilla MH; Leiva KE; Dannuncio V; Viteri M; Rivas M; Kumari N
    Cureus; 2024 Apr; 16(4):e57544. PubMed ID: 38707016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity as a risk factor in atrial fibrillation and heart failure.
    Jurica J; Péč MJ; Benko J; Bolek T; Galajda P; Mokáň M; Samoš M
    J Diabetes Metab Disord; 2024 Jun; 23(1):125-134. PubMed ID: 38932866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
    Vassart J; Didembourg M; Morimont L; Brisbois C; Jamart L; Lebreton A; Mullier F; Donis N; Favresse J; Dogné JM; Douxfils J
    Thromb Res; 2024 Apr; 236():236-239. PubMed ID: 38484630
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing atrial fibrillation in COVID-19: exploring the role of interleukin-6 receptor antagonists.
    Kow CS; Ramachandram DS; Hasan SS
    Expert Rev Cardiovasc Ther; 2023; 21(10):713-714. PubMed ID: 37791465
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel oral anticoagulants in chronic kidney disease: ready for prime time?
    Ashley J; Sood MM
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):201-208. PubMed ID: 29570468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.
    McHorney CA; Crivera C; Laliberté F; Germain G; Wynant W; Lefebvre P
    PLoS One; 2018; 13(4):e0194099. PubMed ID: 29621248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.
    Chokesuwattanaskul R; Thongprayoon C; Tanawuttiwat T; Kaewput W; Pachariyanon P; Cheungpasitporn W
    Pacing Clin Electrophysiol; 2018 Jun; 41(6):627-634. PubMed ID: 29577340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
    Tittl L; Endig S; Marten S; Reitter A; Beyer-Westendorf I; Beyer-Westendorf J
    Int J Cardiol; 2018 Jul; 262():85-91. PubMed ID: 29622509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.
    Potpara TS; Ferro CJ; Lip GYH
    Nat Rev Nephrol; 2018 May; 14(5):337-351. PubMed ID: 29578207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice.
    Li YG; Pastori D; Lip GYH
    Ann Med; 2018 Jun; 50(4):288-302. PubMed ID: 29608110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
    Charlton B; Adeboyeje G; Barron JJ; Grady D; Shin J; Redberg RF
    PLoS One; 2018; 13(3):e0193912. PubMed ID: 29590141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Kirchhof P; Haeusler KG; Blank B; De Bono J; Callans D; Elvan A; Fetsch T; Van Gelder IC; Gentlesk P; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Massaro T; Mont L; Nielsen JC; Nölker G; Piccini JP; De Potter T; Scherr D; Schotten U; Themistoclakis S; Todd D; Vijgen J; Di Biase L
    Eur Heart J; 2018 Aug; 39(32):2942-2955. PubMed ID: 29579168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban.
    Camm AJ; Fox KAA
    Curr Med Res Opin; 2018 Nov; 34(11):1945-1957. PubMed ID: 29672182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants.
    Eikelboom JW; Kozek-Langenecker S; Exadaktylos A; Batorova A; Boda Z; Christory F; Gornik I; Kėkštas G; Kher A; Komadina R; Koval O; Mitic G; Novikova T; Pazvanska E; Ratobilska S; Sütt J; Winder A; Zateyshchikov D
    Br J Anaesth; 2018 Apr; 120(4):645-656. PubMed ID: 29576106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism.
    Simmons B; Wysokinski W; Saadiq RA; Bott-Kitslaar D; Henkin S; Casanegra A; Lenz C; Daniels P; Bjarnason H; Vargas E; Hodge D; Holton SJ; Cerhan JR; Loprinzi C; McBane R
    Eur J Haematol; 2018 Apr; ():. PubMed ID: 29617053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.